Section Arrow
Quote
DRUG.NASDAQ
- Bright Minds Biosciences
Quotes are at least 15-min delayed:2025/06/02 00:21 EDT
Last
 25.95
-1.4 (-5.12%)
Day High 
27.38 
Prev. Close
27.35 
1-M High
37 
Volume 
26.30K 
Bid
25
Ask
27
Day Low
25.2954 
Open
27.25 
1-M Low
26.3011 
Market Cap 
193.73M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 30.16 
20-SMA 30.81 
50-SMA 32.15 
52-W High 79.02 
52-W Low 0.9305 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.20/-5.70
Enterprise Value
193.77M
Balance Sheet
Book Value Per Share
5.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
INABIN8bio0.1446-0.0088-5.74%-- 
BLRXBioLineRx Ltd5.18+1.3891+36.64%-- 
IMNNImunon2.45+0.46+23.12%-- 
NCNANuCana plc0.03525-0.00175-4.73%-- 
MRNAModerna26.58-0.35-1.30%-- 
Quotes are at least 15-min delayed：2025/06/02 00:21 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.